Quality of life with neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) versus adjuvant nivolumab in resectable stage III melanoma: 36-week data from the phase 3 NADINA trial.

Autor: Lucas, Minke W., Arokoski, Reetta, Menzies, Alexander M., Pulleman, Saskia, Saw, Robyn P.M., van Houdt, Winan J., Faries, Mark B, Robert, Caroline, Ascierto, Paolo Antonio, Lebbe, Celeste, Carlino, Matteo S., Kapiteijn, Ellen, Suijkerbuijk, Karijn, Rutkowski, Piotr, Sandhu, Shahneen, Van Der Veldt, Astrid Aplonia Maria, Long, Georgina V., Blank, Christian U., van de Poll-Franse, Lonneke, Lijnsvelt, Judith
Zdroj: Journal of Clinical Oncology; 2024 Supplement 17, Vol. 42, pLBA9584-LBA9584, 83p
Databáze: Supplemental Index